Skip to main content

C1-Inhibitor substitution as ultima ratio therapy in septic shock: experience with 15 patients

Introduction

Plasma C1-Inhibitor (C1-INH) is the major inhibitor of both the classical pathway of complement system and contact activation. A relative deficiency of C1-INH has been proposed as an important contributor to the development of shock and organ failure [1,2]. Among others, our working group has published two cases of successful C1-INH substitution in septic patients recently [3].

Methods

In a retrospective study we investigated data of 15 patients with septic shock who received C1-INH concentrate as ultima ratio therapy. The mean substitutional dosage of C1-INH concentrate (Berinert HS', Centeon) was 10.300 units. Mean values for C1-INH activity, antigenic C1-INH level, fluid balance, hemodynamic and respiratory parameters were compared 24 h prior to 96 h after C1-INH administration.

Results

After substitutional therapy the antigenic C1-INH level increased significantly (from 159 to 228%) while the functional C1-INH activity did not change statistically. The daily fluid balance decreased from +2695 to -186 ml/24 h (P = 0.05), hemodynamic parameters were not affected. There was a good tendency towards higher arterial-to-inspired oxygen ratios (P = 0.55) after C1-INH administration.

Conclusion

Our data show significantly higher antigenic C1-INH levels after substitutional therapy but no difference in C1-INH functional activity. This may be due to complex formation of C1-INH with its target proteases. Prior to C1-INH administration the patients had positive fluid balances and impaired arterial-to-inspired oxygen ratios. If This is looked upon as an equivalent to capillary leakage these results encourage to perform a randomised controlled study on C1-INH substitution in septic patients.

References

  1. Nuijens JH, et al: Proteolytic inactivation of plasma C1 inhibitor in sepsis. J Clin Invest. 1989, 84: 443-10.1172/JCI114185.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  2. Hack CE, et al: C1 -inhibitor substitution therapy in septic shock and in vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Med. 1993, 19: 19-28. 10.1007/BF01738946.

    Article  Google Scholar 

  3. Vangerow B, et al: Clinical improvement after administration of C1 -Inhibitor in two patients with SIRS and capillary leak syndrome. Intensive Care Med. 1996, 22 (suppl 3): 367-

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vangerow, B., Marx, G., Leuwer, M. et al. C1-Inhibitor substitution as ultima ratio therapy in septic shock: experience with 15 patients. Crit Care 2 (Suppl 1), P019 (1998). https://doi.org/10.1186/cc149

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/cc149

Keywords